Could a common diabetes drug mend hearts after failure?

NCT ID NCT07403955

Not yet recruiting Disease control Sponsor: Qilu Hospital of Shandong University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether dapagliflozin, a drug already used for diabetes, can improve heart function in people hospitalized with acute heart failure. About 188 participants will take the drug or not for three months, and doctors will use special ultrasound imaging to measure changes in heart muscle strain. The goal is to see if the drug helps the heart remodel and pump better after a crisis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dapagliflozin (a diabetes drug being tested for heart failure)
What this could lead to: If it works, this could show that dapagliflozin helps the heart recover better after acute failure, potentially leading to a new standard treatment.
What could go wrong: This is a small, early-stage study (188 people) that has not yet started. It only measures heart strain on imaging, not long-term outcomes like survival. The drug may not show meaningful benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

congestive heart failure heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CONGESTIVE HEART FAILURE ACUTE

More trials for these conditions

Other studies related to the condition(s) this trial covers.